Form 8-K

8-K — AIM ImmunoTech Inc.

Accession: 0001493152-26-022891

Filed: 2026-05-14

Period: 2026-05-14

CIK: 0000946644

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0000946644

2026-05-14

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of The

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): May 14, 2026

AIM

IMMUNOTECH INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-27072

52-0845822

(state

or other jurisdiction

(Commission

(IRS

Employer

incorporation)

File

Number)

Identification

No.)

2117

SW Highway 484, Ocala, Florida

34473

(Address

of principal executive offices)

(Zip

Code)

Registrant’s

telephone number, including area code: (352) 448-7797

(Former

name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate

by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933

(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol

Name

of each exchange on which registered

Common

Stock, par value $0.001 per share

AIM

NYSE

American

Item

7.01 Regulation

FD Disclosure.

Furnished

herewith as Exhibit 99.1 is a press release, dated May 14, 2026, related to a Virtual Investor Key Opinion Leader Connect segment (the

“Segment”) in which Professor Casper H.J. van Eijck, MD, PhD, Professor and Pancreato-biliary Surgeon at Erasmus Medical

Center and a consultant for AIM ImmunoTech Inc. (the “Company”), and Thomas K. Equels, MS, JD, the Company’s Chief

Executive Officer, participated. In addition, a video of the Segment was posted on the Virtual Investor website at https://virtualinvestorco.com/aim/.

The

information, including Exhibit 99.1 and the video Segment, referenced herein, is “furnished” and shall not be deemed “filed”

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

It may only be incorporated by reference in another filing under the Securities Exchange Act of 1934, as amended, or the Securities Act

of 1933, as amended, if and to the extent such subsequent filing specifically references the information herein as being incorporated

by reference in such filing. The information, including the Segment, on the website referenced above is not part of this Current Report

on Form 8-K, and any references to such website or any other website are inactive textual references only.

Item

9.01 Financial

Statements and Exhibits.

Exhibit

No.

Description

99.1

Press Release dated May 14, 2026.

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

AIM ImmunoTech Inc.

Dated:

May 14, 2026

By:

/s/

Thomas K. Equels

Thomas

K. Equels, Chief Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

AIM

ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer

Positive

Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial

Segment

featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary Surgeon at Erasmus MC and an oncology consultant for

AIM ImmunoTech, is now available on demand here

OCALA,

Fla., May 14, 2026 / AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced

that Professor Casper H.J. van Eijck, MD, PhD, Professor and Pancreato-biliary Surgeon at Erasmus Medical Center (“Erasmus MC”)

and a consultant for AIM, and AIM Chief Executive Officer Thomas K. Equels, MS, JD, participated in a Virtual Investor KOL Connect

segment.

The

on-demand segment provides investors with an in-depth discussion on AIM’s substantial progress and strategic focus to advance Ampligen®

(rintatolimod) for the treatment of late-stage pancreatic cancer, a lethal malignancy with a significant unmet medical need.

The

Virtual Investor KOL Connect Segment can be accessed here.

Through

these insights from Prof. Dr. van Eijck, a globally recognized pancreatic cancer clinical expert and the foremost expert in the use of

Ampligen in pancreatic cancer, the segment examines Ampligen’s mechanism of action, its potential to provide a positive immunotherapeutic

approach, existing clinical data, development strategy, and anticipated regulatory milestones, supporting AIM’s focused commitment

to advancing a potential new treatment option for patients with late-stage pancreatic cancer.

Developing

Ampligen in the Treatment of Pancreatic Cancer

The

Company has previously reported positive interim progress in both Mid-Year 2025 and Year-End 2025 reports on the ongoing

Phase 2 clinical study evaluating Ampligen in collaboration with with AstraZeneca and its anti-PD-L1 immune checkpoint inhibitor Imfinzi®

(durvalumab) in the treatment of metastatic pancreatic cancer patients post-FOLFIRINOX standard of care (the “DURIPANC” study).

A Mid-Year 2026 report, completion of enrollment and milestones are expected this June, 2026.

See

more information about DURIPANC at ClinicalTrials.gov NCT05927142.

DURIPANC

is a follow-up to the AIM/Erasmus MC Named Patient Program (“NPP”) utilizing Ampligen as a monotherapy in late-stage pancreatic

cancer, where data suggested impressive improvements in survival data:

● Progression-Free

Survival (“PFS”) of 12.6 months compared to 8.6 months for historical controls,

for an improvement of 4 months in PFS

● Overall

Survival (“OS”) of 19.7 months compared to 12.5 months for historical controls,

for an improvement of 7.2 months in OS

● Based

upon stratification for immune marker Neutrophil/Lymphocyte ratios less than 4.5, PFS of

17.7 months compared to 8.6 months for historical controls, for an improvement of 9.1

months in PFS

● Based

upon stratification for immune marker Neutrophil/Lymphocyte ratios less than 4.5, OS of 34.8

months compared to 12.5 months for historical controls, for an improvement of 22.3 months

in OS

● Based

upon stratification for immune marker CA 19-9 less than 1000, PFS of 13.1 months compared

to 8.6 months for historical controls, for an improvement of 4.5 months in PFS

● Based

upon stratification for immune marker CA 19-9 less than 1000, OS of 24.1 months compared

to 12.5 months for historical controls, for an improvement of 11.6 months in OS

● Clinical

experience to date in both the NPP and DURIPANC suggest consistent improvement in Quality

of Life

See

more information in slides 12-14 in Ampligen Breakthroughs in Treating Late-Stage Pancreatic Cancer

Ampligen’s

progress in late-stage pancreatic cancer at Erasmus MC has been published in peer-reviewed oncology journals:

● Rintatolimod

in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell-Mediated

T-Cell Responses (2024)

● Rintatolimod:

A potential treatment in patients with pancreatic cancer expressing Toll-like receptor 3

(2023)

● Rintatolimod

(Ampligen®) Enhances Numbers of Peripheral B Cells and Is Associated with

Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated

with FOLFIRINOX: A Single-Center Named Patient Program (2022)

● Rintatolimod

Induces Antiviral Activities in Human Pancreatic Cancer Cells: Opening for an Anti-COVID-19

Opportunity in Cancer Patients? (2021)

About

AIM ImmunoTech Inc.

AIM

ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod),

for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective

TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For

more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Forward-Looking

Statements

This

press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section

21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. The video segment may also

contain forward-looking statements. Any forward-looking statements set forth in this press release speak only as of the date hereof and

any forward-looking statements in the video segment speak only as of the date thereof. Such forward-looking statements may include statements

relating to: the timing of commencement, enrollment, completion, and results of clinical trials; IP expansion and regulatory progress;

and timing for receiving government approvals, if at all. For all forward-looking statements, the Company claims the protection of the

safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All statements in this

press release and the video segment other than statements of historical fact, including statements regarding the potential of Ampligen’s

mechanism of action, anticipated regulatory milestones, our future results of operations and financial position, our business strategy

and plans, and our objectives for future operations, are forward-looking statements. For both this press release and the video segment,

words such as “believe,” “may,” “might,” “will,” “could,” “should,”

“can,” “estimate,” “continue,” “anticipate,” “intend,” “expect,”

“envision” and similar expressions are intended to identify forward looking statements, but the absence of these words does

not mean that a statement is not forward-looking. All discussions regarding Ampligen’s therapeutic potential in pancreatic cancer

reflect the presenters’ views are based on data from the previously announced, completed Named Patient Program/Early Access Program

and on interim reports regarding an ongoing Phase 2 clinical trial involving co-administration of Ampligen with another drug. As such,

they are interpretations of the significance of available data and analyses and projections by the presenters regarding the potential

that a Phase 3 trial would produce positive results in support of a New Drug Application. See a more detailed analysis of the EAP and

the Phase 2 clinical trial in AIM’s corporate presentation: https://aimimmuno.com/presentations/. The Company does not undertake

to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof, except as required

by applicable law. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple

types of viral diseases, cancers, and immune-deficiency disorders, and disclosures in the Company’s reports filed with the SEC,

on its website, and in its press releases set forth its current and anticipated future activities. These activities are subject to change

for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will

be effective in the treatment of these conditions. Results obtained in preclinical studies do not necessarily predict results in humans.

Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance

can be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject

to many factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at

the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies

will be successful or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that

such studies will yield favorable results, or that future studies will not result in findings that are different from those reported

in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases.

Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property

rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

For

a detailed discussion of risk factors, please review the “Risk Factors” section in the Company’s most recent Annual

Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the SEC. These filings are available at www.sec.gov and

www.aimimmuno.com. The information found on the Company’s website or on other websites referenced or linked to in this press release

(including in the video segment) is not incorporated by reference into this press release and such information is referenced or linked

for reference purposes only.

Investor

Contact:

JTC

Team, LLC

Jenene

Thomas

908.824.0775

AIM@jtcir.com

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (4489 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

May 14, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 14, 2026

Entity File Number

001-27072

Entity Registrant Name

AIM

IMMUNOTECH INC.

Entity Central Index Key

0000946644

Entity Tax Identification Number

52-0845822

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2117

SW Highway 484

Entity Address, City or Town

Ocala

Entity Address, State or Province

Entity Address, Postal Zip Code

34473

City Area Code

(352)

Local Phone Number

448-7797

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.001 per share

Trading Symbol

AIM

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration